Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, ...

The AmeriFlex Group® (or "the firm"), an advisor-owned hybrid RIA recognized for its planning-first approach and innovative succession solutions, today announced that Cambridge Investment Research, ...

The Net Zero Summit 2026 is entering its final countdown ahead of its return to London on 4-5 March 2026 at the QEII Centre in ...

Ben Lloyd explores the key challenges of employing AI in manufacturing and highlights how new plug-and-play solutions are ...

The Trump administration has given corporations plenty of convenient excuses to retreat from their climate commitments, with ...

Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Kansas City has come to national prominence for leading the national “tenant union” movement, organizing massive groups of renters to effectively stop rent increases and get landlords to provide ...

Ardmore Shipping's focus on MR product and chemical tankers positions it to benefit from market inefficiencies and global ...